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The urea cycle disorders (UCDs) are important models for developing gene replacement therapy
for liver diseases. Long-term correction of the most common UCD, ornithine transcarbamylase
(OTC) deficiency, has yet to be achieved in clinical or preclinical settings. The single human
clinical trial using early-generation adenovirus (Ad) failed to show any biochemical correction. In
adult OTC-deficient mice, an E1/E2-deleted Ad vector expressing the mouse OTC gene, but not
the human, was only transiently therapeutic. By using post-transcriptional overexpression in the
context of the less immunogenic helper-dependent adenoviral vector, we achieved metabolic
correction of adult OTC-deficient mice for >6 months. Demonstrating this result were normalized
orotic aciduria, normal hepatic enzyme activity, and elevated OTC RNA and protein levels in the
absence of chronic hepatotoxicity. Overexpressing the human protein may have overcome two
potential mechanisms accounting for poor cross-species complementation: a kinetic block at the
level of mitochondrial import or a dominant negative effect by the mutant polypeptide. These
data represent an important approach for treating human inborn errors of hepatocyte
metabolism like the UCDs that require high-level transduction and gene expression for clinical
correction.
Key Words: liver-directed gene therapy, phosphoenolpyruvate carboxykinase (PEPCK) promoter,
woodchuck hepatitis virus post-transcriptional regulatory element (WPRE)
INTRODUCTION
Because the urea cycle disorders (UCDs) are characterized
by the triad of hyperammonemia, encephalopathy, and
respiratory alkalosis, they are models of classic inborn
errors of hepatocyte metabolism [1,2]. Despite aggressive
pharmacotherapy, patients are at high risk for repeated
episodes of hyperammonemia and cumulative neurolog-
ical morbidity and mortality [3–5]. Hence, risk-benefit
considerations make the development of clinical gene
replacement therapy for this group of disorders appropri-
ate for long-term correction as well as for bridging ther-
apy to alternative treatments such as liver transplantation
[6–9].
One group of researchers achieved partial correction
in a large-animal bovine model of a UCD, citrulline-
mia (argininosuccinic synthetase deficiency), using a
first-generation adenovirus (FGV) despite transduction
of 30% of hepatocytes [10]. Several studies over the
past decade have found the therapeutic effect of sev-
eral different Ad vectors to be transient in ornithine
transcarbamylase (OTC)–deficient mouse models [11–
13]. The longest period of biochemical correction (2
months) was achieved with an E1/E2-deleted Ad
expressing the mouse OTC (mOTC) gene [11]. A rela-
tively high dose (5  1011 total particles per mouse) of
a FGV expressing human OTC (hOTC) could not
correct the biochemical defect in adult OTC-deficient
MOLECULAR THERAPY Vol. 10, No. 3, September 2004492
Copyright B The American Society of Gene Therapy
1525-0016/$30.00
ARTICLE doi:10.1016/j.ymthe.2004.05.036
mice [11]. A report by Ye et al. suggests that the
differences between mouse and human mitochondrial
leader peptide sequences of OTC may lead to ineffi-
cient import of hOTC into mouse mitochondria [14].
An isolated report of short-term correction in spf-ash
mice with FGV expressing hOTC at a relatively low
dose of 5  108 pfu/mouse has not been reproduced
[13].
Morsy et al. showed that an Ad vector expressing
hOTC was therapeutic in neonatal spf-ash mice; however,
measured OTC activity in treated mice was significantly
lower than that in wild-type littermates [12]. This was
attributed to a dominant negative effect of the endoge-
nous mutant protein on the activity of the wild-type
protein delivered by the Ad. Morsy et al. also suggested
that increased enzyme activity in the intestine at early
time points may have contributed to the rapid reduction
of urinary orotic acid [12], and this was consistent with
earlier transgenic studies documenting the importance of
small-bowel expression of OTC [15].
Another obstacle to clinical efficacy is acute toxicity
associated with direct vector–host cell interaction and
the host innate immune response [16–19]. In a phase 1/
2 human clinical trial, researchers administered an E1/
E4-deleted Ad vector expressing hOTC into the right
hepatic artery of human patients with partial OTC
deficiency (OTCD). One patient treated with 6  1011
viral particles per kilogram suffered fatal acute toxicity
[20]. Of concern was the absence of any substantial
metabolic correction as measured by stable isotope
study. One general strategy to reduce a potential host
immune response is to restrict the pattern of transgene
expression by using tissue-restricted promoters. This
may be important for avoiding an adaptive immune
response to the therapeutic protein product [21–23].
Another development that has markedly increased the
therapeutic index for Ad gene therapy has been the
generation of the helper-dependent adenoviral vector
(HDV). This vector should avoid the host cell-mediated
immune response to viral proteins and direct hepato-
toxicity associated with viral gene expression [24]. Ad-
ditionally, with the exception of expression of the
intracellular structural protein dystrophin [25], data
obtained so far with HDVs have focused on secreted
proteins. Hence, the UCDs represent an important mod-
el for developing HDV-mediated correction of intracel-
lular enzymatic deficiencies of hepatocyte metabolism.
Increasing gene expression offers another potential ave-
nue for increasing the therapeutic index, especially for a
non-cell-autonomous process that would allow for an
associated reduction in vector dose. The ability of spe-
cific viruses to enhance gene expression post-transcrip-
tionally could serve well in this arena [26,27]. For
example, Loeb et al. have postulated that the inclusion
of the woodchuck hepatitis virus posttranscriptional
regulatory element (WPRE) in the sense orientation
downstream of the cDNAs will enhance stability of
mRNA [26]. Hence, it may be an effective tool for
increasing the level of protein expression in gene ther-
apy [28].
We hypothesized that by combining HDV-mediated
delivery, tissue-restricted expression of an intracellular
protein product, and post-transcriptional enhancement
of expression using the WPRE, we can achieve high-level
and efficient expression of hOTC and correct the meta-
bolic phenotype in spf-ash mice with little, if any,
chronic toxicity. This would constitute an important
model for correcting a host of inborn errors of hepato-
cyte metabolism including organic acidemias, fatty acid
oxidation defects, and amino acidopathies.
RESULTS
Generation and Characterization of HDVs
The phosphoenolpyruvate carboxykinase (PEPCK) pro-
moter is predominantly expressed in the liver and to
some degree in the kidney [29]. These are also the sites
where the urea cycle is active, making this an appropri-
ate tissue-restricted promoter for expression of UCD
proteins. The region of the rat PEPCK promoter from
–2,088 to +69 bp was both necessary and sufficient to
direct hepatocyte-specific, developmental, hormonal,
and dietary regulation of the gene encoding PEPCK
[30]. We generated two HDV plasmids derived from
the C4HSU plasmid [31]. Both contained the PEPCK
promoter upstream of the hOTC cDNA (Fig. 1A). One
study had shown that the 600-bp WPRE enhanced gene
expression in an orientation-specific but transgene-,
promoter-, and vector-independent manner [32]. Hence,
we inserted this downstream of the hOTC cDNA in one
vector (Fig. 1A). Restriction digestion analysis of vector
and parental plasmid DNA showed the expected bands
and excluded gross vector rearrangements during rescue
(Fig. 1B). Southern hybridization using a packaging
signal-specific probe followed by quantification by
phosphoimaging indicated 0.09% helper contamination
for HDV-hOTC and 0.12% for HDV-hOTC-WPRE, re-
spectively (Fig. 1B, bottom panel).
Long-Term HDV-Mediated Correction of Orotic
Aciduria in OTCD Mice
In OTCD there is accumulation of carbamyl phosphate
that can be diverted to cytoplasmic pyrimidine synthesis.
Hence, OTCD patients and mice have increased excretion
of urinary orotic acid [33,34]. In clinical practice, orotic
aciduria is an important biochemical measure of urea
cycle activity in OTCD. Hence, successful gene replace-
ment therapy of OTCD should normalize urinary con-
centrations of this metabolite. To determine whether
HDV-mediated gene therapy could correct orotic acidu-
ria, we treated spf-ash mice with intravenous injection of
saline, HDV-PEPCK-hOTC, or HDV-PEPCK-hOTC-WPRE.
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Fig. 2 shows the profile of urinary orotic acid excretion.
Spf-ash mice treated with PBS demonstrated consistently
elevated urinary orotic acid compared with wild-type
mice, though with considerable variability that is reflec-
tive of the daily pattern of food and water intake. Mice
treated with 1.0  1013 particles/kg of HDV-PEPCK-hOTC
showed a significant decline in orotic acid concentrations
1 week after injection (115 vs. 29 mM/mol of creatinine
(cr); P = 0.04) (Fig. 2). However, by 2 weeks after injec-
tion, there was no difference between this and the PBS-
treated group. In contrast, urinary orotic acid of mice
treated with 1.0  1013 particles/kg of the WPRE-contain-
ing vector decreased to within the normal range (18 F 7
mM/mol cr; n = 10 age-and sex-matched littermates) 1
week after injection. Thereafter, these mice showed a
complete and prolonged correction of orotic aciduria that
lasted for the duration of the experiment (Fig. 2). A
subgroup of these mice that were not sacrificed at the
endpoint (25 weeks) have continued to show normal
urinary orotic acid at 12 months after injection (n = 2;
data not shown). These mice had no mortality.
Complete Normalization of Hepatic OTC Activity in
HDV-Treated Mice
Histochemical assays on liver sections from mice injected
with HDV-PEPCK-hOTC demonstrated little staining in a
majority of hepatocytes (Figs. 3C and F). This result was
supported by the biochemical assay on liver homoge-
nates (Fig. 3H), which showed hepatic OTC activity
comparable to livers from mice treated with PBS. In
contrast, mice treated with the WPRE-containing vector
demonstrated considerable liver OTC activity by histo-
chemical staining in a majority of hepatocytes (Figs. 3D
and G). Histochemical staining supported the presence of
high-level hepatocyte transduction and transgene expres-
sion required for clinical correction of a defect of hepa-
tocyte metabolism. To quantify this, we measured OTC
activity in homogenized liver in these groups of mice.
The HDV-PEPCK-hOTC-WPRE–treated group had com-
parable activity to that of wild-type mice. Moreover, the
HDV-PEPCK-hOTC-WPRE group had significantly more
activity than PBS-treated (19,000 vs. 852 Amol/h/g; P <
0.0001) or HDV-PEPCK-hOTC–treated groups (19,000 vs.
700 Amol/h/g; P < 0.0001).
Enhanced Steady-State Concentrations of OTC mRNA
and Protein Mediated by WPRE
To determine whether differences in vector transduc-
tion efficiency might account for differences in phe-
notypic correction mediated by HDV-PEPCK-hOTC-
FIG. 2. Long-term correction of orotic aciduria in spf-ash mice by WPRE-
containing HDV. Orotic aciduria was completely abolished in mice treated
with the WPRE-containing HDV, and this effect lasted for >6 months. Values
represent mean F SD of between 4 and 10 determinations. §P < 0.05 HDV-
hOTC vs. PBS; *P < 0.005, bP = 0.02, HDV-hOTC-WPRE vs. PBS; wP < 0.02, zP <
0.005, HDV-hOTC-WPRE vs. HDV-hOTC.
FIG. 1. HDV structure and helper virus contamination.
(A) Schematic showing the two vectors used in this
study. The first contains hOTC cDNA downstream of the
PEPCK promoter (P). In the second construct, WPRE (W)
was inserted downstream of hOTC cDNA in an
orientation- and position-specific manner. C, Ad packa-
ging signal; L-ITR, left inverted terminal repeat; R-ITR,
right inverted terminal repeat. (B) Restriction digests of
viral vector (lanes 1 and 3) and parental plasmid (lanes 2
and 4) DNAs. Arrow indicates the band containing the
bacterial origin of replication and ampicillin resistance
cassette expected in the case of the parental plasmid
only (lanes 2 and 4), but visualized better with the XmnI
digest. Identical bands in vector and plasmid lanes
indicate absence of gross vector rearrangements. After a
prolonged exposure a helper virus-specific band was
apparent in the vector lane (bottom panel). M, 1 kb
molecular weight standard; H, helper virus; 1, HDV-
PEPCK-hOTC; 2, pC4HSU-PEPCK-hOTC; 3, HDV-PEPCK-
hOTC-WPRE; 4, pC4HSU-PEPCK-hOTC-WPRE.
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WPRE vs. the HDV without the WPRE, Southern blot
analyses were done on liver-derived DNAs from mice
at weeks 5 and 25 after injection. Using a probe
specific for vector (hOTC) and a probe specific for an
endogenous mouse gene (Rbbp1) for normalization,
quantitative Southern blot analysis showed comparable
vector DNA for the two HDVs (Fig. 4B). This suggested
that both vectors had similar transduction rates in
liver and that potential differences in infectivity did
not account for the different degree of phenotypic
correction.
Northern hybridization analysis of liver RNA showed
significantly higher steady-state levels of transgene
mRNA in the mice treated with the WPRE-containing
vector (Fig. 5A). After normalizing to mouse Gapdh
mRNA, quantification showed that HDV-PEPCK-hOTC-
WPRE–treated mouse livers had a 9-fold greater amount
of hOTC mRNA when compared with HDV-PEPCK-
hOTC–treated mouse livers. Western blot analysis was
consistent with this finding, with significantly higher
levels of total OTC protein in liver from mice treated
FIG. 4. Efficacy of WPRE-containing vector is not due to differences in
hepatocyte transduction. (A) AscI restriction map for the two vectors used in
the study. Small black bar represents probe used in Southern blotting. (B)
Southern blot. The vector/mouse genome ratio was similar between the two
vectors (quantification shown for week 25). 1, PBS; 2, HDV-hOTC; 3, HDV-
hOTC-WPRE.
FIG. 3. Complete normalization of liver OTC activity in spf-ash mice treated
with WPRE-containing vector. (A) For comparison, OTC histochemical activity
in liver from a wild-type male littermate is shown. Liver tissue from PBS-
injected spf-ash mice shows very low levels of histochemically active OTC,
either at 5 weeks (B) or 25 weeks (E) after treatment. In contrast, mouse liver
from the HDV-PEPCK-hOTC – treated group shows low histochemical staining
above background, at both time points (C and F). In liver from mice treated
with WPRE-containing vector, OTC histochemical activity is similar to wild-
type levels (D and G). (H) Liver OTC activity measured by a quantitative
biochemical assay shows normal levels in the HDV-PEPCK-hOTC-WPRE–
treated group of spf-ash mice at 25 weeks after injection. 1, Wild-type male
littermate; 2, spf-ash, PBS; 3, spf-ash, HDV-PEPCK-hOTC; 4, spf-ash, HDV-
PEPCK-hOTC-WPRE. Values represent mean F SD of three independent
determinations. *P < 0.0001.
FIG. 5. Increased steady-state levels of OTC mRNA and protein in mice treated
with HDV-hOTC-WPRE. (A) Northern blot. The relative intensities of hOTC
mRNA and mouse Gapdh were quantified at week 5 only. At steady state, the
amount of hOTC mRNA was significantly elevated in the livers of spf-ash mice
treated with the WPRE-containing vector compared with the other group (*P <
0.0005 for week 5). 1, PBS-treated mice; 2 and hO, HDV-PEPCK-hOTC –
treated mice; 3 and hO-W, HDV-PEPCK-hOTC-WPRE – treated mice. (B)
Western blot. hOTC (lanes in groups 2 and 3) and mOTC (lanes in group 1)
were detected by a polyclonal antibody generated to hOTC. The OTC protein
was normalized to an internal control band (int. cont.). At steady state, the
amount of hOTC protein was significantly elevated in the livers of spf-ash mice
treated with HDV-PEPCK-hOTC-WPRE (*P < 0.02 for week 5). 1, PBS-treated
mice; 2, and hO, HDV-PEPCK-hOTC – treated mice; 3 and hO-W, HDV-PEPCK-
hOTC-WPRE – treated mice.
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with the WPRE-containing vector (Fig. 5B). The polyclon-
al antibody reacts with both the mouse and human
proteins and detected the mOTC in the PBS-treated spf-
ash mice. The sizes of the detected bands were appropri-
ate based upon respective translation of the open reading
frames.
Tissue-Restricted Expression Alone Does Not Confer
Long-Term Correction
To determine whether the prolonged correction of the
hOTC-WPRE cassette was primarily due to absence of
viral gene expression and/or tissue-restricted expression
of the protein, we generated a FGV vector harboring
the identical PEPCK-hOTC-WPRE transgene. The FGV
vector expressing hOTC from the tissue-restricted
PEPCK promoter (FGV-PEPCK-hOTC-WPRE) was unable
to normalize urinary orotic acid in the affected mice
for a prolonged period, even though the construct
contained the WPRE (Fig. 6A). As shown in Fig. 6A,
a transient decline in urinary orotic acid could not be
sustained. This course of correction is highly reminis-
cent of that obtained by Ye et al. using a E1/E2-deleted
Ad vector expressing the mouse OTC cDNA from the
cytomegalovirus promoter [11]. In contrast to Southern
blot data from HDV-treated mice (Fig. 4B), liver tissue
from FGV-treated mice showed a marked decline in
vector DNA from week 5 to 15 (Fig. 6B), consistent
with the urinary orotic acid data for the latter group
of mice.
Absence of Chronic Toxicity with the HDV
First generation Ad vector treatment is associated with
hepatotoxicity, both early and late after injection
[6,35,36]. Compared with PBS-treated mice, however,
those receiving HDV showed no significant elevation in
liver function tests. Serum ALT at 1 month after injection
was as follows: 52 F 17 U/liter (PBS) vs. 74 F 1 U/liter
(HDV-PEPCK-hOTC) vs. 37 F 12 U/L (HDV-PEPCK-
hOTC-WPRE). Histological analysis confirmed the ab-
sence of hepatitis, lymphocytic infiltration, fibrosis, or
steatosis in PBS- and in HDV-treated mice at both early
and late time points (Fig. 7). In contrast, mice treated
with the first-generation vector expressing hOTC (FGV-
PEPCK-hOTC-WPRE) demonstrated significant hepato-
toxicity. There was evidence of liver injury with variable
extent of hepatocyte anisonucleosis (variations in size,
amount of chromatin, vacuoles, multilobation, and mul-
tiple nuclei), as shown in Fig. 6C. Furthermore, at 1
month after injection the average serum ALT in the
FGV-injected mice was 332 U/liter, which was five times
greater than in untreated or HDV-treated mice.
DISCUSSION
A helper-dependent Ad vector carrying the WPRE and
expressing hOTC in a tissue-restricted fashion was able to
correct the biochemical phenotype in OTCD mice for >6
months. This is the first demonstration of long-term
clinical correction in this model using the human trans-
gene. In fact, our results also demonstrate long-term
clinical correction of an intracellular enzymatic protein
deficiency in hepatocytes by an Ad vector. Together, the
data support a potential approach for correction of ge-
netic deficiencies that require high-level transduction
and gene expression in the liver. Until now, most studies
have focused on correction of metabolic phenotypes of
non-cell-autonomous processes like hemophilia and h-
glucuronidase deficiency. In these conditions, transduc-
FIG. 6. Tissue-restricted expression mediated by FGV-PEPCK-hOTC-WPRE is
unable to achieve long-term correction. (A) A transient drop in orotic acid
production is followed by an upward trend in urinary orotic acid. Note that
urinary orotic acid levels never entered the normal range, as was observed
with HDV-mediated transfer. Values represent mean F SD of between three
and seven determinations. (B) Southern blot shows that FGV-mediated
transfer is accompanied by loss of vector genome between week 5 and 15
after injection. (C) Liver histology shows FGV-mediated hepatotoxicity. Arrows
indicate foci of lymphocytic infiltration consistent with necro-inflammation
and single-cell necrosis of hepatocytes, respectively. The dose was 1  1013
particles/kg in both the HDV and FGV cases.
FIG. 7. Complete absence of liver histopathology in HDV-treated mice when
compared with PBS-treated mice on H and E staining.
MOLECULAR THERAPY Vol. 10, No. 3, September 2004496
Copyright B The American Society of Gene Therapy
ARTICLE doi:10.1016/j.ymthe.2004.05.036
tion of a smaller percentage of target cells could theoret-
ically correct the clinical phenotype by overexpressing a
secreted protein.
Metabolic parameters including serum glutamine and
ammonia have been assessed as endpoints, but because of
the significant variability throughout the day, partially
reflective of food intake, we and others have used urinary
orotic acid as a primary metabolic endpoint of preclinical
efficacy. As in severely affected OTC female patients who
have partial activity of the urea cycle, urinary orotic acid
correlates best with clinical status. Hence, we used this as
our main biochemical and metabolic endpoint for clini-
cal correction. Several groups have attempted to correct
the spf-ash phenotype using Ad vectors in preclinical
studies. In one experiment, Ye et al. showed that a FGV
containing a ubiquitously expressed hOTC cDNA did not
correct the biochemical phenotype, whereas an identical
vector containing mOTC cDNA did so transiently at a
relatively high dose (2  1011–5  1011 total particles/
mouse) [11]. To determine whether overexpression of the
human OTC could overcome the hypothesized kinetic
block of mitochondrial entry, we injected 3  1011
particles/mouse of each vector, a dose similar to what
Ye et al. had shown to work transiently in mice. At 2-and
10-fold lower doses of HDV, there was no correction of
orotic aciduria, despite the WPRE (data not shown). The
extremely short-lived partial correction that we observed
with HDV-PEPCK-hOTC was similar to the pattern
reported for early-generation Ad vectors expressing the
human transgene. Because hOTC is poorly imported into
mouse mitochondria, it may undergo accelerated degra-
dation in the cytoplasm [14]. Furthermore, because
steady-state protein concentration will depend on the
rate of protein turnover, there might not be sufficient
protein for sustained therapeutic effect, thereby explain-
ing the transient correction rather than long-term low-
level correction. In fact, both the western blot analyses
and the histochemical staining of liver tissue show that
the HDV-PEPCK-hOTC – treated mice did not have
steady-state levels of OTC protein (mouse or human)
greater than what is seen in the untreated mice, which
retain f5% residual activity. Our data show that the
WPRE is an effective cis-acting sequence for considerably
enhancing transgene expression, a variable that could
increase the therapeutic index of Ad-mediated gene ther-
apy. One could argue that in human hepatocytes, where
impeded import of hOTC is not an issue, the steady-state
level of protein may be even higher than that observed in
the mouse system. This would make such an approach
even more efficacious in the human setting.
The presence of a potentially nonfunctional, albeit
lower steady-state concentration of mOTC protein may
influence immune responses in gene therapy experi-
ments. These mice are not immune deficient but do
express the mOTC protein. Hence, an immune response
to the very similar hOTC is less likely. In fact, in another
system in which we have compared the B6 mouse im-
mune response to another urea cycle enzyme, arginino-
succinic acid synthetase (ASS), which is similarly
homologous between humans and mice, we could not
detect mouse cytotoxic immune responses to human ASS
(unpublished data). Ye et al. suggested that a cell-medi-
ated immune response to hOTC or to residual viral
protein expression could also contribute to the short
duration of correction that they observed [11,36]. It is
possible that residual viral protein expression in early Ad
vectors may concurrently act as an adjuvant to the host
immune response to the transgene protein. Our data
suggest that we can overcome these potential mecha-
nisms in the absence of viral gene expression with the
HDV and by restricting transgene expression primarily to
hepatocytes. At least in this model, the finding of tran-
sient correction with the FGV carrying an identical trans-
gene, the immunogenic effect of viral proteins with
associated direct toxicity probably constitute the pre-
dominant influences in limiting correction at these
higher doses. We know that liver-specific expression of
secreted proteins can avoid a humoral immune response
in otherwise responsive mice [21,23]. Although the use of
tissue-restricted promoters offers theoretical advantages
even in our case, it alone in the FGV backbone could not
confer clinical correction.
Kiwaki et al. did not observe any correction when the
hOTC cDNA was driven by the ubiquitously expressing
Sra promoter, whereas the same promoter-transgene
combination was therapeutic in spf-ash mice according
to Morsy et al. [12]. In the latter case, it is possible that
neonatal gene therapy induced immune tolerance to the
transgene. From a risk-benefit perspective, severe neona-
tal OTCD would be an optimal candidate disorder for
developing gene replacement therapy. The use of HDV
would minimize concerns of chronic toxicity and hepa-
titis due to the host adaptive immune response.
These studies also demonstrate effective production of
HDVs using a recently described suspension culture [37].
This is an important advance that facilitates the produc-
tion of infectious vectors, with minimal helper virus
contamination. This is crucial for permitting future clin-
ical trials. Although the use of HDVs, tissue-restricted
promoters, and gene-regulatory strategies for increasing
gene expression will improve the therapeutic index of
these therapies and minimize the adaptive immune re-
sponse and chronic toxicity, a remaining obstacle for
translating these findings to the clinic is an acute toxicity
associated with systemic Ad delivery [38]. This acute
toxicity is evident within hours after delivery and is
characterized, in part, by direct interaction of the vector
with host cells, an innate immune response to transduced
cells, and a cytokine response. Ultimately, this acute
toxicity can escalate into a systemic inflammatory re-
sponse that is characterized by an amplification of the
cytokine burst during an intermediate phase of toxicity
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that may be further complicated by de novo viral gene
expression [18,19]. Although HDVs and FGVs probably
have similar acute toxicity profiles, the absence of viral
gene expression in HDVs might attenuate the host re-
sponse during the intermediate phase of toxicity.
In conclusion, we have successfully demonstrated
long-term correction of OTCD in a mouse model by
WPRE-mediated tissue-restricted overexpression of hOTC
from a HDV. Importantly, complete clinical correction
occurred without associated chronic toxicity. Incorpora-
tion of the cis-acting WPRE can increase protein expres-
sion, whereas the tissue-restricted expression might
further decrease an adaptive immune response to the
transgene product, although it alone could not confer
long-term correction in the presence of viral gene expres-
sion. It seems that in this model, the absence of viral gene
expression was the primary variable facilitating long-term
correction. These data also demonstrate correction of an
intracellular enzymatic defect requiring high-level trans-
duction and gene expression. This might constitute a
general approach that improves the therapeutic index
of Ad-mediated gene replacement therapies of enzymatic
deficiencies of hepatocyte metabolism.
MATERIALS AND METHODS
Generation and characterization of Ad vectors. hOTC cDNA with NotI
linkers was cloned downstream of the rat PEPCK promoter to generate
pPEPCK-hOTC. This plasmid was digested with AscI, and the resultant
PEPCK-hOTC fragment inserted into the adenoviral backbone plasmid
pC4HSU [31] to generate the parental HDV plasmid pC4HSU-PEPCK-
hOTC. Plasmid pWPRE was digested with ClaI to release the WPRE, which
was then inserted into the MluI site of pPEPCK-hOTC, to generate
pPEPCK-hOTC-WPRE. The remaining steps to generate the HDV plasmid
pC4HSU-PEPCK-hOTC-WPRE were the same as just mentioned. All clon-
ing sites were confirmed by DNA sequence analysis. The identity of
recombinant HDV plasmids was confirmed by restriction enzyme diges-
tion with HindIII and BamHI.
The HDV plasmids were linearized with PmeI before transfection into
293Cre4 cells. HDVs were rescued and amplified with 293Cre4 cells and
helper virus AdLC8cluc as described in detail elsewhere [39– 41]. Suspen-
sion 293N3Scre8 cells [30] were used in the final step of HDV production
[37]. Purification, quantification by OD260 and viral DNA extraction were
done as described in detail elsewhere [37,41].
For structural characterization, DNA digested with XmnI or BglI was
run on an ethidium bromide – stained 1% agarose gel. For comparison,
the parental plasmid was digested with PmeI in addition to the enzymes
just named. For determination of helper contamination, DNA digested
with BglI was transferred to a nylon membrane for Southern hybridiza-
tion analysis. The [a-32P]dCTP random prime-labeled adenoviral pack-
aging signal probe c [41] was used to distinguish between the 1.6-kb
vector-specific and the 1.0-kb helper-specific bands. Autoradiography of
the blot was conducted using a Storm phosphoimager and quantitated
using the ImageQuant software (Molecular Dynamics, Sunnyvale, CA,
USA).
A FGV was generated using the AdEasy system (Stratagene, La Jolla,
CA, USA) according to the manufacturer’s protocol. Briefly, the PEPCK-
hOTC-WPRE cassette was cloned into a shuttle plasmid, linearized, and
co-transformed with an adenoviral backbone plasmid into Escherichia coli.
Homologous recombination produced a FGV plasmid, which was linear-
ized to expose the inverted terminal repeats and used to transfect 293
cells. The vector FGV-PEPCK-hOTC-WPRE was produced at high titer
through successive rounds of amplification. The vector was titered by
infecting 293 cells in culture at several different dilutions of vector. The
cells were then overlaid with agarose, and individual plaques were
counted after 10 days and used to calculate the viral particle/pfu ratio.
Mouse injection and sample collection. Breeding pairs of spf-ash mice
were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). A
colony was maintained by mating heterozygote females with either wild-
type littermates or hemizygous OTCD males in the Center for Compar-
ative Medicine at Baylor College of Medicine. To account for possible
inter-animal variation, wild-type littermates were used as controls to
obtain baseline values for metabolic and other parameters. In this hypo-
morphic mouse model, there is production of mouse OTC at 5% of
normal [11]. The mice received a normal protein load of regular chow.
All mice used in the study were 12-to 16-week-old OTCD males and their
wild-type male littermates. A standard vector dose of 1.0  1013 particles/
kg (3.0  1011 per mouse) was injected into tail veins of affected mice. As a
control, an equal volume of PBS was injected into tail veins of 10 affected
mice. Blood was obtained by retro-orbital bleeding at specified times
before and after vector administration (3 days before injection; 3 days, 4
weeks, and 25 weeks after injection). Urine was obtained by placing mice
in diuresis cages (Tecniplast, Phoenixville, PA, USA) for 12 h. At weekly
intervals, urine samples were obtained before and after injection. Mice
were sacrificed at specified time points (5 and 25 weeks after injection for
the HDV-injected mice and 5 and 15 weeks for the FGV-injected mice,
respectively) and liver samples processed as mentioned later. Lower vector
doses (5  1012 and 1  1012 particles/kg, respectively) were also injected
into OTCD mice. No differences in appearance or life expectancy were
noted among HDV-and PBS-treated mice.
Biochemical and histochemical assays. Urinary orotic acid was deter-
mined by electrospray tandem mass spectrometry in the Biochemical
Genetics Laboratory at Baylor College of Medicine. Quantification was
accomplished on a Waters 2695 HPLC coupled to a Micromass Quattro LC
mass spectrometer using a variation of the method of Ito et al. [42].
Urinary creatinine was determined by the Jaffe colorimetric method [43].
For OTC enzymatic assay, liver tissue was homogenized in PBS using a
glass homogenizer. The homogenate was centrifuged at maximum speed
(14,000 RPM) for 5 min, supernatant was transferred to a new tube, and
OTC enzyme activity measured as previously described [11]. OTC histo-
chemical staining was done as previously described [11]. On light-micro-
scopic observation, dark brown deposits of lead sulfide indicated the sites
of OTC activity.
Southern, northern, and western analyses. Total DNA was extracted from
mouse liver, and 25 Ag digested with AscI were fractionated on a 1.0%
agarose gel and transferred to a nylon membrane. Total liver RNA was
isolated with TRIzol (Life Technologies, Grand Island, NY, USA) according
to the manufacturer’s protocol, and 20 Ag of RNA fractionated on a 1.2%
glyoxal gel were transferred to a nylon membrane. DNA fragments used as
probes in Southern and northern hybridizations were gel-purified and
labeled with [a-32P]dCTP by random priming. Total liver protein was
isolated, fractionated on a 12% polyacrylamide gel (ISC BioExpress, Kays-
ville, UT, USA), transferred to Immun-Blot PVDF membrane (BioRad,
Hercules, CA, USA), probed with a nonspecific polyclonal antibody
against hOTC (provided by Mendel Tuchman, Children’s National Med-
ical Center, Washington, DC, USA) and immunoreactive OTC detected by
enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ,
USA). Autoradiography of the blots was done using a Storm phosphoim-
ager and quantitated using the ImageQuant software (Molecular Dynam-
ics, Sunnyvale, CA, USA).
Serum chemistry and liver histology. Serum alanine aminotransferase
(ALT) was analyzed at the Center for Comparative Medicine at Baylor
College of Medicine. Histological analyses were done on Sections 4 Am
thick. The sections were fixed in 10% formalin, embedded in paraffin, and
MOLECULAR THERAPY Vol. 10, No. 3, September 2004498
Copyright B The American Society of Gene Therapy
ARTICLE doi:10.1016/j.ymthe.2004.05.036
then stained with H&E using a standard protocol at the Texas Children’s
Hospital Pathology Laboratory.
Statistical analysis. Statistical analysis was limited to Student’s t-test for
unpaired samples. Statistical significance was assigned at P < 0.05. All
results are expressed as mean F SD of at least three independent
observations.
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